Microbix is the world’s largest manufacturer of Dengue virus antigen and makes the antigen used in most of the top selling diagnostic tests.
TORONTO, Canada, Nov. 4, 2010 -- Microbix Biosystems Inc. (MBX:TSX), a Canadian biotechnology company with world-wide markets and focused on large-scale virology, is focusing its efforts on the expanding demand for dengue virus antigen.
Dengue is endemic in much of the tropical world, and traveler’s infections are rising dramatically in the United States and Europe. The World Health Organization estimates over 40% of the world’s population are at risk of contracting dengue hemorrhagic fever, and over 500,000 people are hospitalized each year from this disease. Diagnostic testing and surveillance are important tools in the fight to control the spread of dengue virus.
Microbix has been producing purified dengue virus antigen since 1992. We originally developed this antigen with the Walter Reed Army Institute of Research, who continue to use antigen from Microbix today. Our inactivated Dengue 2 antigen is the main antigen used in 7 of the top 10 selling dengue ELISA, including the growing field of direct dengue antigen detection.
We are currently expanding our efforts into other serotypes of dengue and look forward to offering these to clients soon. Please visit our booth in Hall 3 (Booth K51) to discuss dengue antigen or our future plans for this antigen line.
Earlier this year, Microbix expanded its sales force in Europe by opening a local office in Paris, France. The Company also expanded its efforts in India, and established a distribution centre in China to ease the burden associated with overseas shipping. These new distribution channels, along with a continually expanding and improving product line make Microbix viral antigens the choice of nine of the world’s 10 largest diagnostic manufacturers.
Our antigens include:
• Hepatitis A virus
• Rubella virus
• Dengue virus
• Parainfluenza virus
• Herpes Simplex 1&2
• Measles virus
• Influenza virus
• Varicella-Zoster virus
• Respiratory syncytial virus
• Epstein-Barr virus
Microbix will be exhibiting in Hall 3, Booth K51 as part of the Ontario, Canada pavilion and welcomes new visitors and old friends.
For further information please contact Kevin Koole email@example.com +1-905-361-8910 x228
Microbix Biosystems Inc. specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.